Your session is about to expire
← Back to Search
mRNA-1345 Vaccine for Respiratory Syncytial Virus (RSVictory Trial)
RSVictory Trial Summary
This trial is testing the safety and effectiveness of a new vaccine for RSV (respiratory syncytial virus) that is given with either a seasonal flu vaccine or a new vaccine for SARS-CoV-2 (the virus that causes COVID-19).
RSVictory Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.RSVictory Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am over 50, can care for myself, am medically stable, and can attend study visits.I am over 50, can care for myself, and my health has been stable for the last month.I haven't been in a study or taken experimental treatments in the last 6 months, and I haven't had any vaccines 28 days before or plan to within 28 days after starting this study. I also haven't had bad reactions to vaccines or Guillain-Barré syndrome after a flu shot.I was in Part B of this study, followed all steps, and can visit the study site as needed.I am fully vaccinated for COVID-19 as per local guidelines.I am fully vaccinated for COVID-19 as per local guidelines.I can attend all study visits and have transportation.I'm sorry, I can't provide a summary for this criterion as it is incomplete. Please provide more information.
- Group 1: Part C: mRNA-1345
- Group 2: Part B: mRNA-1345 + Placebo
- Group 3: Part A: mRNA-1345 + Placebo
- Group 4: Part A: mRNA-1345 + Afluria® Quadrivalent
- Group 5: Part A: Afluria® Quadrivalent + Placebo
- Group 6: Part B: mRNA-1345 + mRNA-1273.214
- Group 7: Part B: mRNA-1273.214 + Placebo
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Can people with the required qualifications enroll in this trial today?
"The clinical trial is recruiting at 34 sites across the nation and is looking for 3300 total participants. The study was first posted on 4/1/2022 and was last edited on 8/7/2022 according to information found on clinicaltrials.gov"
To what degree does Afluria® Quadrivalent protect individuals?
"Afluria® Quadrivalent, which is currently in Phase 3 clinical trials, has received a safety score of 3 from our analysts. This signifies that while there is still some testing required to confirm efficacy, the medication has shown to be safe in multiple rounds of clinical trials."
Is this trial widely available in many places throughout the city?
"Patients are currently being recruited at Central Research Associates Inc in Birmingham, Alabama; Revival Research Corporation - Clinedge - PPDS in Doral, Florida; Benchmark Research - Austin - HyperCore - PPDS in Austin, Texas; and 34 other sites."
How many volunteers are needed for this clinical trial?
"In order to move forward, this clinical trial needs 3300 willing and eligible participants. If you meet the requirements and are interested in participating, know that you can do so at Central Research Associates Inc in Birmingham, Alabama or Revival Research Corporation - Clinedge - PPDS in Doral, Florida."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What site did they apply to?
Why did patients apply to this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Sun Research Institute: < 24 hours
Average response time
- < 1 Day
Share this study with friends
Copy Link
Messenger